share_log

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

世紀陽光生物製藥報告2024年第三季度業績:截至目前的收入增長54%
Accesswire ·  11/06 08:00

FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 third quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $8,435,178 for the three months ended September 30, 2024, a 42% increase over gross revenues of $5,957,668 for same period in 2023. For the nine-month period ended September 30, 2024, gross revenues were $25,279,291, compared to gross revenue of $16,412,586 for the same period in 2023, an increase of 54%. These increases were a result of new product launches and expanded marketing and sales efforts by the Company's wholly owned Canadian subsidiary, Nora Pharma Inc.

FORt LAUDERDALE,FL / ACCESSWIRE / 2024年11月6日 / 世紀陽光生物製藥公司(納斯達克:SBFM)("公司"),一家在腫瘤學和抗病毒等多種治療領域提供和研究挽救生命藥物的藥品公司,今天宣佈已向證券交易委員會提交了其2024年第三季度報告。公司報告顯示,截至2024年9月30日三個月的毛收入爲8,435,178美元,比2023年同期的5,957,668美元增長了42%。截至2024年9月30日的九個月期間,毛收入爲25,279,291美元,而2023年同期的毛收入爲16,412,586美元,增長了54%。這些增長是公司全資擁有的加拿大子公司Nora Pharma Inc.推出新產品和擴大營銷和銷售努力的結果。

The following are highlights of the Company's 2024 third quarter results:

以下是公司2024年第三季度業績亮點:

  • Sales in the third quarter grew to $8,435,178, compared to $5,957,668 during the same period last year, an increase of 42%.

  • 第三季度銷售額達到8,435,178美元,而去年同期爲5,957,668美元,增長了42%。

  • Sales of 8,435,178 in the third quarter were down 9% from the second quarter sales of $9,303,067 but up 12% over first quarter sales of $7,541,046.

  • 第三季度銷售額爲8,435,178美元,比第二季度的9,303,067美元下降了9%,但比第一季度的7,541,046美元增長了12%。

  • Net loss for the three months ended September 30, 2024, was $(1,197,803) compared to a net loss of $(651,482) during the same period of 2023, an increase of 84%.

  • 截至2024年9月30日三個月的淨虧損爲(1,197,803)美元,而2023年同期的淨虧損爲(651,482)美元,增長了84%。

The following are highlights of the Company's 2024 year-to-date (YTD) results:

以下是公司2024年的年-to-date(YTD)業績亮點:

  • In terms of YTD results, sales grew to $25,279,291, compared to $16,412,586 during the same period last year, an increase of 54%.

  • 就YTD的結果而言,銷售額增至25,279,291美元,而去年同期爲16,412,586美元,增長了54%。

  • Net loss for the nine months ended September 30, 2024, was $(2,975,904) compared to a net loss of $(3,256,020) during the same period of 2023, a decrease of 9%.

  • 截至2024年9月30日九個月的淨虧損爲(2,975,904)美元,而2023年同期的淨虧損爲(3,256,020)美元,減少了9%。

  • Shareholders' Equity grew to $25,039,312, an 18% increase over Shareholders' Equity of $21,207,361 at December 31, 2023.

  • Shareholders' Equity grew to $25,039,312, an 18% increase over Shareholders' Equity of $21,207,361 at December 31, 2023.

"At Sunshine Biopharma, we are relentlessly pursuing profitability," expressed Dr. Steve Slilaty, CEO. "Our dedicated team is implementing cutting-edge strategies and enhancing our operations to foster sustainable growth. We are unwavering in our commitment to delivering value to our stakeholders, and we firmly believe our hard work will pave the way for success."

"At Sunshine Biopharma, we are relentlessly pursuing profitability," expressed Dr. Steve Slilaty, CEO. "Our dedicated team is implementing cutting-edge strategies and enhancing our operations to foster sustainable growth. We are unwavering in our commitment to delivering value to our stakeholders, and we firmly believe our hard work will pave the way for success."

The following are key metrics contained in the Company's Statement of Operations for the three- and nine-month periods ended September 30, 2024:

The following are key metrics contained in the Company's Statement of Operations for the three- and nine-month periods ended September 30, 2024:

2024Q3

2023Q3

2024YTD

2023YTD

Sales

$8,435,178

$5,957,668

$25,279,291

$16,412,586

Gross Profit

$2,866,151

$1,990,256

$7,576,745

$5,771,125

General & Administrative Expenses

$3,972,504

$2,769,730

$11,351,144

$9,369,203

Net Loss

($1,197,803)

($651,482)

($2,975,904)

($3,256,020)

2024Q3

2023年第三季度

2024年累計營運

2023年累計營運

銷售

$8,435,178

$5,957,668

$25,279,291

$16,412,586

毛利潤

$2,866,151

$1,990,256

$7,576,745

$5,771,125

普通及管理費用

$3,972,504

$2,769,730

$11,351,144

$9,369,203

淨虧損

($1,197,803)

($651,482)

($2,975,904)

($3,256,020)

About Sunshine Biopharma Inc.

關於世紀陽光生物製藥公司。

Sunshine Biopharma currently has 63 generic prescription drugs on the market in Canada and 32 additional drugs scheduled to be launched in the remainder of 2024 and in 2025. Among the new drugs to be launched in 2024 is NIOPEG, a biosimilar of NEULASTA. Like NEULASTA, NIOPEG is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy.

世紀陽光生物目前在加拿大市場上有63種常規處方藥,並計劃在2024年底和2025年推出32種額外的藥物。在2024年即將推出的新藥中,有一種名爲NIOPEG,是NEULASTA的生物仿製藥。與NEULASTA一樣,NIOPEG是一種長效重組人粒細胞集落刺激因子(纖維粘合素)製劑。它適用於接受抗腫瘤治療的非骨髓惡性腫瘤患者以減少感染髮生率。

In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: .

此外,Sunshine Biopharma正在進行一項專有藥物開發計劃,其中包括(i)K1.1 mRNA,一種mRNA-脂質納米粒子,以治療肝癌,以及(ii)PLpro蛋白酶抑制劑,一種用於治療SARS冠狀病毒感染的小分子。

Safe Harbor Forward-Looking Statements

相關鏈接:

This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.

本新聞稿包含基於Sunshine Biopharma,Inc.(本公司)當前預期,預測和假設的前瞻性聲明,這些聲明涉及風險以及可能導致實際結果和結論與預期有所不同的不確定性。這些聲明出現在本新聞稿中,包括所有不以事實爲根據的聲明,涉及本公司的意圖,信念或當前期望,包括涉及本公司藥物開發活動,財務表現和未來發展的聲明。這些風險和不確定性在本公司向美國證券交易委員會(SEC)提交的文件和報告中進一步描述。由於本公司在向SEC提交的文件中不時詳細說明的多種因素,實際結果和某些事件的時間可能會與前瞻性聲明中預計的差異很大。本新聞稿中引用了本公司最近公佈於SEC的謹慎聲明和風險因素。

For Additional Information:

其他信息:

Sunshine Biopharma Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com

Sunshine Biopharma聯繫方式:
財務總監Camille Sebaaly
直線電話:514-814-0464
電子郵件:camille.sebaaly@sunshinebiopharma.com

SOURCE: Sunshine Biopharma, Inc.

來源:世紀陽光生物製藥公司


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論